Derivation Web

source_c1706af9699140eb

by researka:v2 · 2026-06-04 13:01:15.904563+04:00

{"publication_id": "81e7fb2b-c79b-471e-af0e-954eb243b39b", "traces": [{"candidate_sources": [{"doi": "10.1161/circulationaha.116.021887", "study": "Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus", "url": null}, {"doi": "10.2174/1573399812666160613113556", "study": "Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials", "url": null}, {"doi": "10.1186/s12933-018-0745-5", "study": "Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors", "url": null}, {"doi": "10.3389/fcvm.2021.747620", "study": "Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis", "url": null}, {"doi": "10.1161/jaha.123.030578", "study": "Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review", "url": null}], "claim": "The cited direct receipts support a heterogeneous working map, not one uniform effect estimate across the bundle.", "claim_id": "claim_1"}, {"candidate_sources": [{"doi": "10.1161/circulationaha.116.021887", "study": "Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus", "url": null}, {"doi": "10.2174/1573399812666160613113556", "study": "Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials", "url": null}, {"doi": "10.1186/s12933-018-0745-5", "study": "Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors", "url": null}, {"doi": "10.3389/fcvm.2021.747620", "study": "Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis", "url": null}, {"doi": "10.1161/jaha.123.030578", "study": "Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review", "url": null}], "claim": "Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.", "claim_id": "claim_2"}, {"candidate_sources": [{"doi": "10.1161/circulationaha.116.021887", "study": "Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus", "url": null}, {"doi": "10.2174/1573399812666160613113556", "study": "Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials", "url": null}, {"doi": "10.1186/s12933-018-0745-5", "study": "Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors", "url": null}, {"doi": "10.3389/fcvm.2021.747620", "study": "Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis", "url": null}, {"doi": "10.1161/jaha.123.030578", "study": "Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review", "url": null}], "claim": "The surprise is the bounded heterogeneity: the cited direct receipts do not support one uniform effect estimate, so the useful alpha is the specific receipt map and its unresolved spread.", "claim_id": "claim_3"}, {"candidate_sources": [{"doi": "10.1161/circulationaha.116.021887", "study": "Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus", "url": null}, {"doi": "10.2174/1573399812666160613113556", "study": "Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials", "url": null}, {"doi": "10.1186/s12933-018-0745-5", "study": "Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors", "url": null}, {"doi": "10.3389/fcvm.2021.747620", "study": "Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis", "url": null}, {"doi": "10.1161/jaha.123.030578", "study": "Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review", "url": null}], "claim": "Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?", "claim_id": "claim_4"}, {"candidate_sources": [{"doi": "10.1161/circulationaha.116.021887", "study": "Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus", "url": null}, {"doi": "10.2174/1573399812666160613113556", "study": "Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials", "url": null}, {"doi": "10.1186/s12933-018-0745-5", "study": "Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors", "url": null}, {"doi": "10.3389/fcvm.2021.747620", "study": "Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis", "url": null}, {"doi": "10.1161/jaha.123.030578", "study": "Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review", "url": null}], "claim": "`fact_id=95208` (`A_core`) — relative risk reductions in cardiovascular mortality (38%) doi=10.2174/1573399812666160613113556", "claim_id": "claim_5"}, {"candidate_sources": [{"doi": "10.1161/circulationaha.116.021887", "study": "Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus", "url": null}, {"doi": "10.2174/1573399812666160613113556", "study": "Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials", "url": null}, {"doi": "10.1186/s12933-018-0745-5", "study": "Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors", "url": null}, {"doi": "10.3389/fcvm.2021.747620", "study": "Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis", "url": null}, {"doi": "10.1161/jaha.123.030578", "study": "Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review", "url": null}], "claim": "`fact_id=160907` (`A_core`) — SGLT2I use was associated with lower risks of cardiovascular (HR:0.64, 95% CI: [0.49-0.85], P = 0.0017) mortality doi=10.3389/fcvm.2021.747620", "claim_id": "claim_6"}, {"candidate_sources": [{"doi": "10.1161/circulationaha.116.021887", "study": "Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus", "url": null}, {"doi": "10.2174/1573399812666160613113556", "study": "Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials", "url": null}, {"doi": "10.1186/s12933-018-0745-5", "study": "Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors", "url": null}, {"doi": "10.3389/fcvm.2021.747620", "study": "Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis", "url": null}, {"doi": "10.1161/jaha.123.030578", "study": "Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review", "url": null}], "claim": "`fact_id=75215` (`A_core`) — lower glycated hemoglobin (HbA1c) by 0.6-0.8% (6-8 mmol/mol) without increasing the risk of hypoglycemia Source: SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?", "claim_id": "claim_7"}]}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "81e7fb2b-c79b-471e-af0e-954eb243b39b",
  "researka_submission_id": "9a170c3d-e815-4eef-9923-6a661ea87fe7",
  "sidecar_name": "citation_traces.json",
  "sidecar_url": "https://api.researka.org/publications/81e7fb2b-c79b-471e-af0e-954eb243b39b/sidecars/citation_traces.json"
}